Redeye: InDex Pharmaceuticals Q4 2022 - Phase lll prospects at a discount
Redeye leaves its comments on InDex following the company’s Q4 report. We adjust our forecasts according to the delay of CONCLUDE and additional capital need, which lowers our valuation. At yesterday’s closing price, the market values InDex below its net cash position, which is remarkable.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/